AGILE THERAPEUTICS INC Quarterly Nonoperating Income (Expense) in USD from Q1 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Agile Therapeutics Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2017 to Q2 2024.
  • Agile Therapeutics Inc Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$9.13M, a 793% decline year-over-year.
  • Agile Therapeutics Inc Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$2.3M, a 113% decline year-over-year.
  • Agile Therapeutics Inc annual Nonoperating Income (Expense) for 2023 was $5.42M, a 75.9% decline from 2022.
  • Agile Therapeutics Inc annual Nonoperating Income (Expense) for 2022 was $22.5M.
  • Agile Therapeutics Inc annual Nonoperating Income (Expense) for 2021 was -$62K, a 97.8% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$2.3M -$9.13M -$10.4M -793% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $8.14M $4.04M +$2.72M +207% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $5.42M -$417K -$3.37M -114% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $8.78M $3.2M -$9.58M -74.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $18.4M $1.32M -$4.91M -78.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $23.3M $1.32M +$805K +157% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $22.5M $2.95M +$120K +4.24% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $22.3M $12.8M +$13.8M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $8.57M $6.23M +$7.22M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $1.36M $513K +$1.42M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$62K $2.83M +$3.71M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-28
Q3 2021 -$3.77M -$998K -$130K -15% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$3.64M -$986K -$199K -25.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$3.44M -$906K -$640K -241% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$2.8M -$879K -$963K -1146% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-23
Q3 2020 -$1.84M -$868K -$935K -1396% Jul 1, 2020 Sep 30, 2020 10-Q/A 2021-12-30
Q2 2020 -$902K -$787K -$850K -1349% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-26
Q1 2020 -$52K -$266K -$304K -800% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $252K $84K +$167K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-30
Q3 2019 $85K $67K +$244K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$159K $63K +$260K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$419K $38K +$302K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 -$721K -$83K +$169K +67.1% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$890K -$177K +$224K +55.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-28
Q2 2018 -$1.11M -$197K +$253K +56.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$1.37M -$264K +$126K +32.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-03
Q4 2017 -$1.49M -$252K Oct 1, 2017 Dec 31, 2017 10-K 2020-02-20
Q3 2017 -$401K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 -$450K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 -$390K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.